{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:14:14Z","timestamp":1757704454019},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Turkiye Egitim Vakfi","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Diabetes Endocrinol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>Patients with lipodystrophy are at high risk for chronic complications of diabetes. Recently, we have reported 18 diabetic foot ulcer episodes in 9 subjects with lipodystrophy. This current study aims to determine risk factors associated with foot ulcer development in this rare disease population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ninety metreleptin na\u00efve patients with diabetes registered in our national lipodystrophy database were included in this observational retrospective cohort study (9 with and 81 without foot ulcers).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients with lipodystrophy developing foot ulcers had longer diabetes duration (<jats:italic>p<\/jats:italic>\u2009=\u20090.007), longer time since lipodystrophy diagnosis (<jats:italic>p<\/jats:italic>\u2009=\u20090.008), and higher HbA1c levels (<jats:italic>p<\/jats:italic>\u2009=\u20090.041). Insulin use was more prevalent (<jats:italic>p<\/jats:italic>\u2009=\u20090.003). The time from diagnosis of diabetes to first foot ulcer was shorter for patients with generalized lipodystrophy compared to partial lipodystrophy (<jats:italic>p<\/jats:italic>\u2009=\u20090.036). Retinopathy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), neuropathy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), peripheral artery disease (<jats:italic>p<\/jats:italic>\u2009=\u20090.001), and kidney failure (<jats:italic>p<\/jats:italic>\u2009=\u20090.003) were more commonly detected in patients with foot ulcers. Patients with foot ulcers tended to have lower leptin levels (<jats:italic>p<\/jats:italic>\u2009=\u20090.052). Multiple logistic regression estimated significant associations between foot ulcers and generalized lipodystrophy (OR: 40.81, 95% CI: 3.31\u2013503.93, <jats:italic>p<\/jats:italic>\u2009=\u20090.004), long-term diabetes (\u2265\u200915 years; OR: 27.07, 95% CI: 2.97\u2013246.39, <jats:italic>p<\/jats:italic>\u2009=\u20090.003), and decreased eGFR (OR: 13.35, 95% CI: 1.96\u201390.67, <jats:italic>p<\/jats:italic>\u2009=\u20090.008).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study identified several clinical factors associated with foot ulceration among patients with lipodystrophy and diabetes. Preventive measures and effective treatment of metabolic consequences of lipodystrophy are essential to prevent the occurrence of foot ulcers in these high-risk individuals.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40842-021-00132-9","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T02:22:52Z","timestamp":1633054972000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk factors for diabetic foot ulcers in metreleptin na\u00efve patients with lipodystrophy"],"prefix":"10.1186","volume":"7","author":[{"given":"O","family":"Saydam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Ozgen Saydam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SC","family":"Adiyaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Sonmez Ince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MA","family":"Eren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FE","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Dagdeviren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Balci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Altay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Bayraktar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EA","family":"Oral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"132_CR1","doi-asserted-by":"crossref","unstructured":"Akinci B, Meral R, Oral EA. Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities. Curr Diabetes Rep 2018, 18(12).","DOI":"10.1007\/s11892-018-1099-9"},{"key":"132_CR2","doi-asserted-by":"crossref","unstructured":"Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, Cheung HC, Bradt P, Foss de Freitas MC, Montenegro RM, et al. Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. J Clin Endocrinol Metab. 2019;104(11):5120\u201335.","DOI":"10.1210\/jc.2018-02730"},{"issue":"12","key":"132_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11892-018-1100-7","volume":"18","author":"B Akinci","year":"2018","unstructured":"Akinci B, Meral R, Oral EA. Update on Therapeutic Options in Lipodystrophy. Curr Diab Rep. 2018;18(12):139.","journal-title":"Curr Diab Rep"},{"issue":"8","key":"132_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMoa012437","volume":"346","author":"EA Oral","year":"2002","unstructured":"Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570\u20138.","journal-title":"N Engl J Med"},{"key":"132_CR5","doi-asserted-by":"crossref","unstructured":"Saydam O, Ozgen Saydam B, Adiyaman CS, Sonmez Ince M, Eren MA, Keskin FE, Bilen H, Dagdeviren M, Kaya S, Akinci G, et al: Diabetic Foot Ulcers: A Neglected Complication of Lipodystrophy. Diabetes Care 2020.","DOI":"10.2337\/dc20-1655"},{"issue":"8","key":"132_CR6","doi-asserted-by":"publisher","first-page":"e0182081","DOI":"10.1371\/journal.pone.0182081","volume":"12","author":"M Narres","year":"2017","unstructured":"Narres M, Kvitkina T, Claessen H, Droste S, Schuster B, Morbach S, Rumenapf G, Van Acker K, Icks A. Incidence of lower extremity amputations in the diabetic compared with the non-diabetic population: A systematic review. PLoS One. 2017;12(8):e0182081.","journal-title":"PLoS One"},{"issue":"11","key":"132_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/dme.13054","volume":"33","author":"JW Walsh","year":"2016","unstructured":"Walsh JW, Hoffstad OJ, Sullivan MO, Margolis DJ. Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med. 2016;33(11):1493\u20138.","journal-title":"Diabet Med"},{"issue":"1","key":"132_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2017","unstructured":"Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136\u201354.","journal-title":"Diabetes Care"},{"issue":"5","key":"132_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.mcna.2013.03.007","volume":"97","author":"AJ Boulton","year":"2013","unstructured":"Boulton AJ. The pathway to foot ulceration in diabetes. Med Clin North Am. 2013;97(5):775\u201390.","journal-title":"Med Clin North Am"},{"issue":"Suppl 1","key":"132_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/dc20-S002","volume":"43","author":"A American Diabetes","year":"2020","unstructured":"American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):14\u201331.","journal-title":"Diabetes Care"},{"issue":"12","key":"132_CR11","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1093\/cid\/cis346","volume":"54","author":"BA Lipsky","year":"2012","unstructured":"Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132\u201373.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"132_CR12","doi-asserted-by":"publisher","first-page":"e0199052","DOI":"10.1371\/journal.pone.0199052","volume":"13","author":"JG Lima","year":"2018","unstructured":"Lima JG, Nobrega LHC, Lima NN, Dos Santos MCF, Silva PHD, Baracho MFP, Lima DN, de Melo Campos JTA, Ferreira LC, Freire Neto FP, et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. PLoS One. 2018;13(6):e0199052.","journal-title":"PLoS One"},{"issue":"7","key":"132_CR13","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1210\/jc.2016-1005","volume":"101","author":"B Akinci","year":"2016","unstructured":"Akinci B, Onay H, Demir T, Ozen S, Kayserili H, Akinci G, Nur B, Tuysuz B, Nuri Ozbek M, Gungor A, et al. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey. J Clin Endocrinol Metab. 2016;101(7):2759\u201367.","journal-title":"J Clin Endocrinol Metab"},{"key":"132_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","volume":"72","author":"B Akinci","year":"2017","unstructured":"Akinci B, Onay H, Demir T, Savas-Erdeve S, Gen R, Simsir IY, Keskin FE, Erturk MS, Uzum AK, Yaylali GF, et al. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy. Metabolism. 2017;72:109\u201319.","journal-title":"Metabolism"},{"issue":"1","key":"132_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/cen.13732","volume":"89","author":"B Akinci","year":"2018","unstructured":"Akinci B, Unlu SM, Celik A, Simsir IY, Sen S, Nur B, Keskin FE, Ozgen Saydam B, Kutbay Ozdemir N, Sarer Yurekli B, et al. Renal complications of lipodystrophy: A closer look at the natural history of kidney disease. Clin Endocrinol (Oxf). 2018;89(1):65\u201375.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"132_CR16","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1210\/jc.2003-032140","volume":"89","author":"ED Javor","year":"2004","unstructured":"Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, Turman MA, Blackett PR, Savage DB, O\u2019Rahilly S, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004;89(7):3199\u2013207.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"132_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","volume":"59","author":"E Safar Zadeh","year":"2013","unstructured":"Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE, Gorden P. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131\u20137.","journal-title":"J Hepatol"},{"issue":"2","key":"132_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","volume":"51","author":"I Hussain","year":"2019","unstructured":"Hussain I, Patni N, Garg A. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. Pathology. 2019;51(2):202\u201312.","journal-title":"Pathology"},{"issue":"6","key":"132_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.7547\/0980489","volume":"98","author":"JM Robbins","year":"2008","unstructured":"Robbins JM, Strauss G, Aron D, Long J, Kuba J, Kaplan Y. Mortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration? J Am Podiatr Med Assoc. 2008;98(6):489\u201393.","journal-title":"J Am Podiatr Med Assoc"},{"issue":"24","key":"132_CR20","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","volume":"376","author":"DG Armstrong","year":"2017","unstructured":"Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017;376(24):2367\u201375.","journal-title":"N Engl J Med"},{"issue":"10","key":"132_CR21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.nmd.2017.05.015","volume":"27","author":"G Akinci","year":"2017","unstructured":"Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, Yaylali GF, et al. Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study. Neuromuscul Disord. 2017;27(10):923\u201330.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"132_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2337\/diacare.22.1.157","volume":"22","author":"GE Reiber","year":"1999","unstructured":"Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJ. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22(1):157\u201362.","journal-title":"Diabetes Care"},{"key":"132_CR23","doi-asserted-by":"crossref","unstructured":"Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, Lavery LA, LeMaster JW, Mills JL, Sr., Mueller MJ, et al: Comprehensive foot examination and risk assessment. Endocr Pract 2008, 14(5):576\u2013583.","DOI":"10.4158\/EP.14.5.576"},{"key":"132_CR24","doi-asserted-by":"crossref","unstructured":"Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, Lavery LA, Lemaster JW, Mills JL, Mueller S. MJ et al: Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31(8):1679\u201385.","DOI":"10.2337\/dc08-9021"},{"issue":"10","key":"132_CR25","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.2337\/diacare.27.10.2376","volume":"27","author":"SA Bus","year":"2004","unstructured":"Bus SA, Maas M, Cavanagh PR, Michels RP, Levi M. Plantar fat-pad displacement in neuropathic diabetic patients with toe deformity: a magnetic resonance imaging study. Diabetes Care. 2004;27(10):2376\u201381.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"132_CR26","first-page":"63","volume":"27","author":"JA Mayfield","year":"2004","unstructured":"Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM, American Diabetes A. Preventive foot care in diabetes. Diabetes Care. 2004;27(Suppl 1):63\u20134.","journal-title":"Diabetes Care"},{"issue":"2","key":"132_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/jama.293.2.217","volume":"293","author":"N Singh","year":"2005","unstructured":"Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217\u201328.","journal-title":"JAMA"},{"issue":"3","key":"132_CR28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","volume":"64","author":"EA Oral","year":"2019","unstructured":"Oral EA, Gorden P, Cochran E, Araujo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Brown RJ. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine. 2019;64(3):500\u201311.","journal-title":"Endocrine"},{"issue":"3","key":"132_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","volume":"60","author":"RJ Brown","year":"2018","unstructured":"Brown RJ, Oral EA, Cochran E, Araujo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Gorden P. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine. 2018;60(3):479\u201389.","journal-title":"Endocrine"},{"issue":"Suppl 1","key":"132_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/dmrr.2705","volume":"32","author":"RJ Hinchliffe","year":"2016","unstructured":"Hinchliffe RJ, Brownrigg JR, Andros G, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, Reekers J, Shearman CP, Zierler RE, et al. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes Metab Res Rev. 2016;32(Suppl 1):136\u201344.","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"132_CR31","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1161\/ATVBAHA.113.301933","volume":"33","author":"G Bidault","year":"2013","unstructured":"Bidault G, Garcia M, Vantyghem MC, Ducluzeau PH, Morichon R, Thiyagarajah K, Moritz S, Capeau J, Vigouroux C, Bereziat V. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2013;33(9):2162\u201371.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Clinical Diabetes and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-021-00132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-021-00132-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-021-00132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T02:37:11Z","timestamp":1633055831000},"score":1,"resource":{"primary":{"URL":"https:\/\/clindiabetesendo.biomedcentral.com\/articles\/10.1186\/s40842-021-00132-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["132"],"URL":"https:\/\/doi.org\/10.1186\/s40842-021-00132-9","relation":{},"ISSN":["2055-8260"],"issn-type":[{"value":"2055-8260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research use of the data collected was approved by the Institutional Review Board (IRB) of the Dokuz Eylul University, Izmir, Turkey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"For this retrospective study, data were collected under the oversight of Dokuz Eylul University Ethics Committee. Patients gave consent to use anonymous data for research purposes. The images used in the manuscript are entirely unidentifiable and there are no personal details on individuals reported within the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EAO reports the following conflicts: Grant support: Aegerion Pharmaceuticals (now Amryt Pharma), Ionis Pharmaceuticals, Akcea Therapeutics, Gemphire Therapeutics, GI Dynamics (current), AstraZeneca (past two years). Consultant or Advisor: AstraZeneca, Thera Therapeutics, and BMS (past), Aegerion Pharmaceuticals (now Amryt Pharma), Regeneron Pharmaceuticals (current). Drug support: Aegerion Pharmaceuticals (now Amryt Pharma), Akcea Therapeutics, Rhythm Pharmaceuticals (all current). Other support: Aegerion Pharmaceuticals (now Amryt Pharma), Regeneron Pharmaceuticals (current). BA has attended Scientific Advisory Board Meetings organized by Aegerion Pharmaceuticals (now Amryt Pharma) and Regeneron Pharmaceuticals and has received honoraria as a speaker from AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis. Other authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}